Amgen's stock price target was raised to $410 following positive results from its experimental drug dazodalibep in a late-stage trial for Sjögren's disease. The drug showed significant improvement in patients' symptoms, with effects seen as early as week 4 and lasting through week 48. This success boosted investor confidence, leading to a 4.34% rise in Amgen's stock price. The development highlights Amgen's strong position in biotech innovation and potential growth in treating autoimmune diseases.
Amgen's stock is trading at USD 411.50 on Pluang as of Sep 23, 2026 21:02 WIB, slightly up by 0.31% for the day. The company's market capitalization stands at $221.79 billion, reflecting its significant presence in the health sector. Despite recent gains, most Pluang users are selling, with 89% of order activity on the platform being sell orders.
